Molecular remodeling of adipose tissue is associated with metabolic recovery after weight loss surgery.
Bariatric surgery
Dyslipidemia
Methylomic
Obesity
Remission
Subcutaneous adipose tissue
Transcriptomic
Type 2 diabetes
Whole genome
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
23 06 2022
23 06 2022
Historique:
received:
13
04
2022
accepted:
13
06
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Bariatric surgery is an effective therapy for individuals with severe obesity to achieve sustainable weight loss and to reduce comorbidities. Examining the molecular signature of subcutaneous adipose tissue (SAT) following different types of bariatric surgery may help in gaining further insight into their distinct metabolic impact. Subjects undergoing biliopancreatic diversion with duodenal switch (BPD-DS) showed a significantly higher percentage of total weight loss than those undergoing gastric bypass or sleeve gastrectomy (RYGB + SG) (41.7 ± 4.6 vs 28.2 ± 6.8%; p = 0.00005). Individuals losing more weight were also significantly more prone to achieve both type 2 diabetes and dyslipidemia remission (OR = 0.75; 95%CI = 0.51-0.91; p = 0.03). Whole transcriptome and methylome profiling showed that bariatric surgery induced a profound molecular remodeling of SAT at 12 months postoperative, mainly through gene down-regulation and hypermethylation. The extent of changes observed was greater following BPD-DS, with 61.1% and 49.8% of up- and down-regulated genes, as well as 85.7% and 70.4% of hyper- and hypomethylated genes being exclusive to this procedure, and mostly associated with a marked decrease of immune and inflammatory responses. Weight loss was strongly associated with genes being simultaneously differentially expressed and methylated in BPD-DS, with the strongest association being observed for GPD1L (r Present findings point to the greater SAT molecular remodeling following BPD-DS as potentially linked with higher metabolic remission rates. These results will contribute to a better understanding of the metabolic pathways involved in the response to bariatric surgery and will eventually lead to the development of gene targets for the treatment of obesity. Trial registration ClinicalTrials.gov NCT02390973.
Sections du résumé
BACKGROUND
Bariatric surgery is an effective therapy for individuals with severe obesity to achieve sustainable weight loss and to reduce comorbidities. Examining the molecular signature of subcutaneous adipose tissue (SAT) following different types of bariatric surgery may help in gaining further insight into their distinct metabolic impact.
RESULTS
Subjects undergoing biliopancreatic diversion with duodenal switch (BPD-DS) showed a significantly higher percentage of total weight loss than those undergoing gastric bypass or sleeve gastrectomy (RYGB + SG) (41.7 ± 4.6 vs 28.2 ± 6.8%; p = 0.00005). Individuals losing more weight were also significantly more prone to achieve both type 2 diabetes and dyslipidemia remission (OR = 0.75; 95%CI = 0.51-0.91; p = 0.03). Whole transcriptome and methylome profiling showed that bariatric surgery induced a profound molecular remodeling of SAT at 12 months postoperative, mainly through gene down-regulation and hypermethylation. The extent of changes observed was greater following BPD-DS, with 61.1% and 49.8% of up- and down-regulated genes, as well as 85.7% and 70.4% of hyper- and hypomethylated genes being exclusive to this procedure, and mostly associated with a marked decrease of immune and inflammatory responses. Weight loss was strongly associated with genes being simultaneously differentially expressed and methylated in BPD-DS, with the strongest association being observed for GPD1L (r
CONCLUSIONS
Present findings point to the greater SAT molecular remodeling following BPD-DS as potentially linked with higher metabolic remission rates. These results will contribute to a better understanding of the metabolic pathways involved in the response to bariatric surgery and will eventually lead to the development of gene targets for the treatment of obesity. Trial registration ClinicalTrials.gov NCT02390973.
Identifiants
pubmed: 35739539
doi: 10.1186/s12967-022-03485-6
pii: 10.1186/s12967-022-03485-6
pmc: PMC9219157
doi:
Banques de données
ClinicalTrials.gov
['NCT02390973']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
283Subventions
Organisme : CIHR
ID : TB2-138776
Pays : Canada
Informations de copyright
© 2022. The Author(s).
Références
Am J Clin Nutr. 2005 Jul;82(1 Suppl):222S-225S
pubmed: 16002825
Diabetes. 2005 Aug;54(8):2277-86
pubmed: 16046292
Obes Surg. 2019 Sep;29(9):3030-3038
pubmed: 31190263
Obes Surg. 2019 Jan;29(1):3-14
pubmed: 30293134
Surg Obes Relat Dis. 2020 Apr;16(4):509-519
pubmed: 32008978
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
Obes Surg. 2021 Aug;31(8):3833-3847
pubmed: 34002289
Clin Nutr. 2020 Feb;39(2):592-598
pubmed: 30948220
Epigenetics. 2019 May;14(5):421-444
pubmed: 30915894
Obes Surg. 2020 Jul;30(7):2620-2630
pubmed: 32170551
Can J Diabetes. 2018 Apr;42 Suppl 1:S10-S15
pubmed: 29650080
Clin Epigenetics. 2021 May 1;13(1):100
pubmed: 33933146
PLoS One. 2015 May 04;10(5):e0125718
pubmed: 25938420
Int J Obes (Lond). 2015 Jan;39(1):85-97
pubmed: 24566855
NPJ Genom Med. 2018 Jan 29;3:4
pubmed: 29387454
High Throughput. 2020 Mar 20;9(1):
pubmed: 32244851
J Intern Med. 2020 Aug;288(2):219-233
pubmed: 32406570
J Clin Endocrinol Metab. 2014 Mar;99(3):898-907
pubmed: 24423338
Obes Surg. 2014 Feb;24(2):197-204
pubmed: 24105406
Diabetes Care. 2019 Feb;42(2):331-340
pubmed: 30665965
Front Physiol. 2020 Jan 29;10:1607
pubmed: 32063863
Genome Biol. 2015 Jan 22;16:8
pubmed: 25651499
Surg Obes Relat Dis. 2020 Jan;16(1):128-136
pubmed: 31708383
Surg Obes Relat Dis. 2013 Sep-Oct;9(5):708-13
pubmed: 22551577
Sci Rep. 2021 Oct 26;11(1):21067
pubmed: 34702864
Obes Surg. 2016 Aug;26(8):1794-8
pubmed: 26803753
Int J Mol Sci. 2020 Jun 24;21(12):
pubmed: 32599690
Nutrition. 2020 Feb;70:110499
pubmed: 31655468
Int J Obes (Lond). 2008 Feb;32(2):292-303
pubmed: 17848939
Consens Statement. 1991 Mar 25-27;9(1):1-20
pubmed: 1760489
N Engl J Med. 2020 Aug 20;383(8):721-732
pubmed: 32813948
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Front Genet. 2021 May 19;12:620740
pubmed: 34093637
Front Endocrinol (Lausanne). 2021 Jun 24;12:628907
pubmed: 34248836
Obes Surg. 2019 Nov;29(11):3493-3499
pubmed: 31256357
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
JAMA Surg. 2018 May 1;153(5):427-434
pubmed: 29214306
Gastroenterology. 2017 May;152(7):1780-1790
pubmed: 28193516
BMC Genomics. 2018 Dec 7;19(1):888
pubmed: 30526554
Ann Surg Innov Res. 2016 Jan 21;10:1
pubmed: 26807142
Obes Surg. 2017 Jul;27(7):1645-1650
pubmed: 28050789
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185664
J Gastrointest Surg. 2008 Feb;12(2):250-5
pubmed: 18071836
Cell Rep. 2013 Apr 25;3(4):1020-7
pubmed: 23583180
Epigenetics. 2010 Aug 16;5(6):527-38
pubmed: 20505344
Circ Res. 2016 May 27;118(11):1844-55
pubmed: 27230645
Obes Res. 2001 Mar;9(3):188-95
pubmed: 11323444
Nat Rev Endocrinol. 2019 Sep;15(9):507-524
pubmed: 31296970
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Obes Surg. 2007 Nov;17(11):1421-30
pubmed: 18219767
J Lipid Res. 2008 Feb;49(2):308-23
pubmed: 17986714
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
Ann Surg. 2016 Dec;264(6):1029-1037
pubmed: 26764870
Surg Obes Relat Dis. 2015 May-Jun;11(3):489-506
pubmed: 26093765
Surg Endosc. 2007 Aug;21(8):1397-402
pubmed: 17332953
Oxid Med Cell Longev. 2019 Dec 6;2019:3940739
pubmed: 31885787
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Sci Rep. 2017 May 11;7(1):1799
pubmed: 28496128
J Lipid Res. 2015 Oct;56(10):1985-92
pubmed: 26239051
Int J Obes (Lond). 2017 Feb;41(2):309-316
pubmed: 27840413
Obes Surg. 2015 Sep;25(9):1584-93
pubmed: 25676155
Nat Commun. 2019 Sep 13;10(1):4179
pubmed: 31519890
Obes Surg. 2009 Mar;19(3):332-8
pubmed: 18719968
Curr Drug Targets. 2012 Mar;13(3):432-9
pubmed: 22206249
Biomolecules. 2019 Dec 09;9(12):
pubmed: 31835423
Diabetes. 2017 Nov;66(11):2743-2755
pubmed: 28835473
Endocrinology. 2015 Apr;156(4):1316-29
pubmed: 25646712
Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1608-14
pubmed: 19644053
Biochem Soc Trans. 2006 Apr;34(Pt 2):213-6
pubmed: 16545079
EBioMedicine. 2019 Jun;44:489-501
pubmed: 31221584
Clin Epigenetics. 2020 Jan 20;12(1):14
pubmed: 31959221
Int J Mol Sci. 2020 Aug 21;21(17):
pubmed: 32825788
Obes Surg. 2017 Sep;27(9):2308-2316
pubmed: 28439748
Int J Obes (Lond). 2015 Jun;39(6):910-9
pubmed: 25783037
Obes Surg. 2018 Jan;28(1):176-186
pubmed: 28735374
Surg Clin North Am. 2016 Aug;96(4):815-26
pubmed: 27473803
Epigenomics. 2012 Jun;4(3):325-41
pubmed: 22690668